Publications dans lesquelles il/elle collabore avec ARANTXA ISLA RUIZ (45)

2024

  1. Optimizing Antibiotic Therapy for Stenotrophomonas maltophilia Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach

    Antibiotics, Vol. 13, Núm. 6

  2. Streptococcus pneumoniae eta Haemophilus influenzae bakterio-espezieek eragindako infekzio inbaditzaile eta ez-inbaditzaileak: txertaketaren eraginak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 45, pp. 71-92

2023

  1. Ceftaroline and Avibactam Removal by Continuous Renal Replacement Therapies: An in vitro Study

    Blood Purification, Vol. 52, Núm. 5, pp. 464-473

  2. Extended infusion of piperacillin/tazobactam: pharmacokinetics in critically ill patients

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Pharmacokinetic/Pharmacodynamic Analysis of Oral Calcium Fosfomycin: Are Urine Levels Sufficient to Ensure Efficacy for Urinary Tract Infections?

    Pharmaceutics, Vol. 15, Núm. 4

2022

  1. Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study

    Journal of Intensive Care, Vol. 10, Núm. 1

2021

  1. Evaluation of the adequacy of the antimicrobial therapy of invasive Haemophilus influenzae infections: A pharmacokinetic/pharmacodynamic perspective

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 2, pp. 65-71

  2. Oral calcium fosfomycin: Pharmacokinetic/pharmacodynamic study

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 76-78

  3. Pharmacokinetic/pharmacodynamic evaluation of the antimicrobial therapy of pneumococcal invasive disease in adults in post-PCV13 vaccine period in Madrid, Spain

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 10, pp. 2145-2152

  4. Population pharmacokinetics of levetiracetam and dosing evaluation in critically ill patients with normal or augmented renal function

    Pharmaceutics, Vol. 13, Núm. 10

  5. Pseudomonas aeruginosa susceptibility in spain: Antimicrobial activity and resistance suppression evaluation by pk/pd analysis

    Pharmaceutics, Vol. 13, Núm. 11

  6. Quantification of ceftaroline in human plasma using high‐performance liquid chromatography with ultraviolet detection: Application to pharmacokinetic studies

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective

    International Journal of Infectious Diseases, Vol. 93, pp. 329-338

  2. Novel population pharmacokinetic model for linezolid in critically ill patients and evaluation of the adequacy of the current dosing recommendation

    Pharmaceutics, Vol. 12, Núm. 1

2019

  1. Application of pharmacokinetic/pharmacodynamic analysis to evaluate the adequacy of antimicrobial therapy for pediatric acute otitis media in Spain before and after the introduction of the PCV7 vaccine

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 121-129

  2. Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 380-386

  3. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

    Journal of Critical Care, Vol. 50, pp. 69-76

  4. Susceptibility of Pseudomonas aeruginosa and antimicrobial activity using PK/PD analysis: an 18-year surveillance study

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 626-633

2018

  1. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review

    Clinical Pharmacokinetics, Vol. 57, Núm. 9, pp. 1107-1121